Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Bought by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 153.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,189,601 shares of the company’s stock after purchasing an additional 1,326,497 shares during the period. Loomis Sayles & Co. L P owned about 2.41% of Myriad Genetics worth $59,973,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Dynamic Technology Lab Private Ltd acquired a new position in Myriad Genetics in the third quarter worth approximately $350,000. Fisher Asset Management LLC grew its holdings in shares of Myriad Genetics by 47.8% in the 3rd quarter. Fisher Asset Management LLC now owns 602,842 shares of the company’s stock worth $16,512,000 after acquiring an additional 195,094 shares during the last quarter. Algert Global LLC raised its position in shares of Myriad Genetics by 135.2% during the third quarter. Algert Global LLC now owns 21,280 shares of the company’s stock worth $583,000 after purchasing an additional 12,232 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Myriad Genetics by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,083,302 shares of the company’s stock valued at $29,672,000 after purchasing an additional 41,374 shares during the last quarter. Finally, Intech Investment Management LLC boosted its position in shares of Myriad Genetics by 32.0% in the 3rd quarter. Intech Investment Management LLC now owns 29,055 shares of the company’s stock valued at $796,000 after purchasing an additional 7,043 shares during the period. 99.02% of the stock is currently owned by institutional investors.

Myriad Genetics Trading Up 2.4 %

Shares of MYGN opened at $15.49 on Monday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average price is $22.26 and its 200 day moving average price is $24.49. Myriad Genetics, Inc. has a twelve month low of $14.72 and a twelve month high of $29.30.

Insider Activity

In related news, Director Colleen F. Reitan sold 46,012 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total value of $1,286,035.40. Following the completion of the sale, the director now directly owns 42,533 shares in the company, valued at approximately $1,188,797.35. The trade was a 51.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Paul J. Diaz sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at $22,067,327.54. The trade was a 1.53 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,012 shares of company stock worth $1,900,485. 2.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have commented on MYGN. Scotiabank upped their price objective on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Tuesday, August 13th. Piper Sandler reduced their price target on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. Wells Fargo & Company initiated coverage on shares of Myriad Genetics in a research report on Tuesday, August 27th. They set an “overweight” rating and a $35.00 price objective on the stock. StockNews.com lowered Myriad Genetics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Morgan Stanley lowered their price target on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday, November 18th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and an average target price of $27.36.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.